Biocon’s Liraglutide will be marketed under two brand names — Liraglutide Biocon for diabetes (generic version of Victoza) and Biolide for chronic weight management (generic version of Saxenda). This drug-device combination offers an affordable alternative for patients suffering from type 2 diabetes and obesity, conditions that have been rising globally.
“The launch of our gLiraglutide for diabetes and obesity in the U.K. marks a significant milestone for Biocon. Making this GLP-1 peptide more accessible and affordable to patients is a testament to our unwavering commitment to enhancing healthcare outcomes across the globe. The timely launch will offer healthcare providers and patients affordable access to this drug and help fulfill an unmet need,” Siddharth Mittal, CEO and Managing Director of Biocon, said.
Biocon has ambitious plans to expand the reach of its generic Liraglutide into other European markets, the U.S., and select “Markets of the World” (MoW) geographies.The company also aims to broaden its portfolio of GLP-1 peptide products, reinforcing its position in this high-growth therapeutic segment.
The Role of GLP-1 in Diabetes and Weight Management GLP-1 receptor agonists like Liraglutide are widely used in diabetes management due to their ability to regulate blood sugar levels, enhance insulin secretion and inhibit glucagon release.
Additionally, they contribute to weight loss by slowing gastric emptying and reducing appetite, making them effective for obesity treatment. Given the growing prevalence of type 2 diabetes and obesity, GLP-1 therapies are increasingly recognised as essential in managing these conditions.
Shares of Biocon slipped over 3% to touch an intraday low of ₹302.2 apiece on the BSE in the morning session on Friday. The stck traded in the red by 2.42% at ₹304.5 at around 10:15 am.
Catch live market updates with CNBC-TV18.com’s blog
